Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (10 / 21 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Changes were made to this summary to match those made to the health professional version.
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Pituitary Carcinomas Treatment
Standard Treatment Options for Pituitary CarcinomasStandard treatment options for pituitary carcinomas include the following:Surgery.Dopamine agonists, such as bromocriptine, pergolide, quinagolide, and cabergoline, for prolactin (PRL)-producing carcinomas.Somatostatin analogues, such as octreotide, for growth hormone (GH)-producing and thyroid-stimulating hormone (TSH)-producing carcinomas.Adjuvant radiation therapy, which does not appear to change the disease's outcome.Chemotherapy, which is of little benefit.Some reports indicate that as many as 88% of pituitary carcinomas are endocrinologically active, and adrenocorticotrophin hormone-secreting tumors are the most common. Treatments for patients with pituitary carcinomas are palliative, with the mean survival time ranging from 2 years to 2.4 years, though several case reports of long-term survivors have been published.[2,3,4,5]Treatment options for patients with pituitary carcinomas include resection and dopamine agonists for
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Stages of Adult Brain Tumors
There is no standard staging system for adult brain and spinal cord tumors.The extent or spread of cancer is usually described as stages. There is no standard staging system for brain and spinal cord tumors. Brain tumors that begin in the brain may spread to other parts of the brain and spinal cord, but they rarely spread to other parts of the body. Treatment of brain and spinal cord tumors is based the following:The type of cell in which the tumor began.Where the tumor formed in the brain or spinal cord.The amount of cancer left after surgery.The grade of the tumor.Treatment of brain tumors that have spread to the brain from other parts of the body is based on the number of tumors in the brain.Imaging tests may be repeated after surgery to help plan more treatment.Some of the tests and procedures used to diagnose a brain or spinal cord tumor may be repeated after treatment to find out how much tumor is left.
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Stages of Childhood Brain Stem Glioma
The plan for cancer treatment depends on whether the tumor is in one area of the brain or has spread throughout the brain.Staging is the process used to find out how much cancer there is and if cancer has spread. It is important to know the stage in order to plan treatment. There is no standard staging system for childhood brain stem glioma. Instead, the plan for cancer treatment depends on whether the tumor is diffuse (spread throughout the brain) or focal (in one area of the brain):Diffuse intrinsic pontine glioma is a tumor that has spread widely throughout the brain stem. A biopsy is usually not done for this type of brain stem glioma and it is not removed by surgery. A diffuse intrinsic pontine glioma is usually diagnosed using imaging studies.Focal or low-grade glioma is a tumor that is in one area of the brain stem. A biopsy may be done and the tumor removed during the same surgery.The information from tests and procedures done to detect (find) childhood brain stem glioma is
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Childhood Brain Stem Glioma
Childhood brain stem glioma is a disease in which benign (noncancer) or malignant (cancer) cells form in the tissues of the brain stem. The brain stem is the part of the brain connected to the spinal cord. It is located in the lowest part of the brain,just above the back of the neck. The brain stem is the part of the brain that controls breathing,heart rate,and nerves and muscles used in ...
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Treatment of Low-Risk Neuroblastoma
Low-risk neuroblastoma represents nearly one-half of all newly diagnosed patients. The success of prior Children's Oncology Group (COG) clinical trials has contributed to the continued reduction in therapy for select patients with neuroblastoma.The COG low-risk group assignment criteria are described in Table 6. Table 6. Children's Oncology Group (COG) Neuroblastoma Low-Risk Group Assignment Schema Used for COG-P9641 and COG-A3961 StudiesaINSS StageAgeMYCNStatusINPC ClassificationDNA PloidybINPC = International Neuroblastoma Pathologic Classification; INSS = International Neuroblastoma Staging System.a The COG-P9641 and COG-A3961 trials established the current standard of care for neuroblastoma patients in terms of risk group assignment and treatment strategies.b DNA Ploidy: DNA Index (DI) > 1 is favorable, = 1 is unfavorable; hypodiploid tumors (with DI 1 (DI < 1 [hypodiploid] to be considered favorable ploidy).c INSS stage
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (08 / 12 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
About This PDQ Summary
Most patients with high-grade astrocytomas or gliomas will eventually have tumor recurrence, usually within 3 years of original diagnosis but perhaps many years after initial treatment. Disease may recur at the primary tumor site, at the margin of the resection/radiation bed, or at noncontiguous central nervous system sites. Systemic relapse is rare but may occur. At the time of recurrence, a complete evaluation for extent of relapse is indicated for all malignant tumors. Biopsy or surgical resection may be necessary for confirmation of relapse because other entities, such as secondary tumor and treatment-related brain necrosis, may be clinically indistinguishable from tumor recurrence. The need for surgical intervention must be individualized on the basis of the initial tumor type, the length of time between initial treatment and the reappearance of the mass lesion, and the clinical picture. Patients for whom initial treatment fails may benefit from additional treatment.